CYTOMEDIX CEO MARTIN ROSENDALE DISCUSSES
COMPANY IN INTERVIEW WITH
THE WALL STREET TRANSCRIPT
Rockville, MD, August 19, 2008 – Cytomedix, Inc. (AMEX:
GTF), today announced that The Wall Street
Transcript (TWST) has published an in-depth interview with Chief Executive Officer Martin Rosendale.
The interview, which was published in the August 18th issue of TWST, is available on the Cytomedix web
site (www.cytomedix.com) or to subscribers at TWST’s web site (www.twst.com).
During the interview, Mr. Rosendale noted that following the launch earlier this year of the Company’s
proprietary AutoloGel™ System, a point-of-care system for the management of chronic wounds, his
priority remains advancing sales of the AutoloGel™ System and working with the Company’s sales
executives “to initiate commercial contracts, facilitate payment and reimbursement opportunities, and
move the sales of the AutoloGel™ System forward,” Mr. Rosendale said.
In addition to the Company’s work in chronic wounds, Mr. Rosendale reported that Cytomedix has
identified compounds with related properties such as angiogenesis, the production of blood vessels, and
anti-inflammatory properties. “We recently announced that we are developing a peptide, CT-112, which
is an anti-inflammatory peptide that may be active for the treatment of inflammatory diseases such as
Rheumatoid Arthritis, Crohn’s Disease, Tissue Reperfusion Injury and other related medical conditions,”
Mr. Rosendale added.
Mr. Rosendale also stated that the Company’s long term vision is to achieve a leadership position in the
field of advanced tissue regeneration technologies. “Cytomedix will continue to develop and market
products that support the needs of patients with debilitating and life-threatening conditions. Our clinical
success will result from the logical application of sophisticated biological therapies to treat complex
clinical problems, and our commercial success will be a result of an intense focus on therapies with
sound pharmacoeconomic benefits,” he added.ABOUT CYTOMEDIX
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from platelet
releasates for use on wounds and other applications. The current offering is the AutoloGel™ System, a
process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet
releasates, and fibrin matrix. Additional information regarding Cytomedix is available at:
http://www.cytomedix.com.
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to historical facts are forward-looking statements
that are intended to fall within the safe harbor rule for such statements under the Private Securities
Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which
are beyond Cytomedix's ability to predict or control, including among others, the outcome of development
or regulatory review of CT-112, commercial success or acceptance by the medical community, and
competitive responses. CT-112 was introduced as a therapeutic candidate with an FDA Pre-IND meeting
in 1995. It is uncertain whether the company will obtain the funds necessary for development, or whether
current market conditions will support a renewed effort to develop CT-112. These forward-looking
statements are subject to known and unknown risks and uncertainties that could cause actual events to
differ from the forward-looking statements. More information about some of these risks and uncertainties
may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.
Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to
update or revise any forward-looking statements, whether as a result of new information, changed
circumstances or future events or for any other reason.
|
